Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (HRTX) announced its financial results for Q4 and FY 2021, reporting net product sales of $20.7 million and $86.3 million, respectively. The net loss decreased to $54.6 million for Q4 2021, improving from $62.3 million in Q4 2020. Key highlights include the successful launch of ZYNRELEF, now covering 7 million procedures annually, with net sales reaching $2.9 million. Anticipated guidance for Q1 2022 oncology care franchise sales is $20 million to $22 million. The company aims to moderate cash usage as sales grow.
- ZYNRELEF's net sales reached $0.8 million in Q4 2021, with a significant reorder rate from over 300 unique accounts.
- Expanded indication for ZYNRELEF, covering approximately 7 million procedures annually.
- Oncology Care Franchise net product sales stabilized, with guidance for Q1 2022 expected between $20 million and $22 million.
- Total net loss for FY 2021 was $220.7 million, with cash reserves decreasing to $157.6 million.
- Q4 2021 oncology care product sales decreased to $19.9 million from $20.6 million in Q4 2020.
- Net cash used for operating activities increased to $203.4 million in FY 2021 compared to $184.8 million in FY 2020.
SAN DIEGO, Feb. 28, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted recent corporate updates.
Recent Corporate Updates
Acute Care Franchise
- ZYNRELEF:
- The ZYNRELEF (bupivacaine and meloxicam) extended-release solution New Drug Application (NDA) was approved by the U.S. Food and Drug Administration (FDA) in May 2021. In December 2021, the FDA approved our supplemental New Drug Application (sNDA) for ZYNRELEF, which significantly expanded the indication statement, now covering approximately 7 million procedures annually. ZYNRELEF is currently indicated for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. The FDA also agreed to Heron's proposal for a second sNDA, planned for later this year, designed to further expand the indication statement.
- ZYNRELEF became commercially available in the U.S. on July 1, 2021, and net product sales for the three and twelve months ended December 31, 2021 were
$0.8 million and$2.9 million , respectively.
- During the first two quarters of commercial launch ended December 31, 2021, over 300 unique accounts purchased ZYNRELEF with
70% of those accounts reordering the product. ZYNRELEF end-user (hospitals and ambulatory surgical centers (ASC)) demand units' volume sales increased by126% in the fourth quarter over the prior quarter.
- As of February 25, 2022, ZYNRELEF has received 260 formulary approvals, with over a
90% hospital approval rate, and over60% of formulary approvals have been for unrestricted use. Over 100 additional formulary review meetings are scheduled through March 31, 2022.
- Multiple commercial and Medicaid payers covering over 120 million lives have agreed to reimburse ZYNRELEF outside of the surgical bundle payment for surgeries performed in ASCs, with many of these covered lives also having their hospital outpatient procedures reimbursed outside the surgical bundle payment. Commercial and Medicaid payers represent more than
80% of our target patients in the outpatient setting. On November 2, 2021, we were issued a specific C-code (C9088) for separate reimbursement in the ASC setting of care effective January 1, 2022.
- In the fourth quarter of 2021, Heron received FDA approval of two manufacturing supplements to the NDA for ZYNRELEF to add a large-scale secondary supplier of our proprietary polymer and to add larger-scale manufacturing of ZYNRELEF. These approvals will allow for the manufacturing of millions of doses of ZYNRELEF annually at a significantly reduced cost of products sales.
- NDA Submission for HTX-019 for Prevention of PONV in Adults Under Review: A 505(b)(2) NDA for HTX-019 for the prevention of postoperative nausea and vomiting (PONV) in adults was submitted to the FDA in November 2021. The FDA accepted the NDA for filing and set a Prescription Drug User Fee Act (PDUFA) goal date of September 17, 2022.
Oncology Care Franchise
- 2021 Oncology Care Franchise Net Product Sales: For the three and twelve months ended December 31, 2021, oncology care franchise net product sales were
$19.9 million and$83.4 million , respectively, compared to$20.6 million and$88.6 million , respectively, for the same periods in 2020. During 2021, Heron's oncology care franchise net product sales have stabilized with moderate growth expected in 2022.
CINVANTI®
- Net Product Sales: Net product sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2021 were
$17.4 million and$73.5 million , respectively, compared to$20.3 million and$87.8 million , respectively, for the same periods in 2020.
- In the fourth quarter of 2021, Heron received FDA approval of a manufacturing supplement to the NDA for CINVANTI to add larger-scale manufacturing of CINVANTI. This approval will significantly reduce the cost of products sales.
SUSTOL®
- Net Product Sales: Net product sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2021 were
$2.5 million and$9.9 million , respectively, compared to$0.3 million and$0.8 million , respectively, for the same periods in 2020.
- 2022 Oncology Care Franchise Net Product Sales Guidance: Heron currently expects the first quarter of 2022 net product sales for the oncology care franchise in the range of
$20 million to$22 million . The Company is not providing full-year 2022 financial guidance at this time due to the uncertainty around the COVID-19 pandemic and its impact on patient care.
"2021 was a tremendous year for Heron. The approval and successful commercial launch of ZYNRELEF was a game-changing milestone for patients, healthcare providers, and pain management. We are extremely pleased with the very positive feedback from patients and surgeons about the benefits of ZYNRELEF, which has resulted in a high reorder rate. With our new broader label for ZYNRELEF and the recent rapid decline of COVID, we expect to significantly expand ZYNRELEF's commercial footprint this year," said Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron. "In oncology care, our CINV portfolio has stabilized and is poised for sales growth in 2022."
Financial Results
Net product sales for the three and twelve months ended December 31, 2021 were
Heron's net loss for the three and twelve months ended December 31, 2021 was
As of December 31, 2021, Heron had cash, cash equivalents and short-term investments of
Conference Call and Webcast
Heron will host a conference call and webcast on February 28, 2022 at 4:30 p.m. ET. The conference call can be accessed by dialing 877-311-5906 for domestic callers and 281-241-6150 for international callers. Please provide the operator with the passcode 9276143 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About ZYNRELEF for Postoperative Pain
ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first modified-release local anesthetic to be classified by the FDA as an "extended-release" product because ZYNRELEF is also the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. ZYNRELEF was initially approved by the FDA in May 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF's indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. In September 2020, the European Commission granted a marketing authorization for ZYNRELEF for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. As of January 1, 2021, ZYNRELEF is approved in 31 European countries including the countries of the European Union and European Economic Area and the United Kingdom.
Please see full prescribing information, including Boxed Warning, at www.ZYNRELEF.com.
About HTX-019 for PONV
HTX-019 is an IV injectable emulsion formulation designed to directly deliver aprepitant, the active ingredient in EMEND® (aprepitant) capsules, which is the only substance P/neurokinin-1 (NK1) receptor antagonist (RA) to be approved in the U.S. for the prevention of PONV in adults. The FDA-approved dose of oral EMEND is 40 mg for PONV prevention, which is given within 3 hours prior to induction of anesthesia for surgery. In a Phase 1 clinical trial, 32 mg of HTX-019 as a 30-second IV injection was demonstrated to be bioequivalent to oral aprepitant 40 mg. The NDA for HTX-019 for PONV was submitted in November 2021 and the FDA set a PDUFA goal date of September 17, 2022.
About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention
CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK1 RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND® capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK1 RA to significantly reduce nausea and vomiting in both the acute phase (0–24 hours after chemotherapy) and the delayed phase (24–120 hours after chemotherapy). The FDA-approved dosing administration included in the U.S. prescribing information for CINVANTI include 100 mg or 130 mg administered as a 30-minute IV infusion or a 2-minute IV injection.
Please see full prescribing information at www.CINVANTI.com.
About SUSTOL for CINV Prevention
SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 RA that utilizes Heron's Biochronomer® drug delivery technology to maintain therapeutic levels of granisetron for ≥5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL's efficacy and safety in more than 2,000 patients with cancer. SUSTOL's efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0–24 hours after chemotherapy) and delayed phase (24–120 hours after chemotherapy).
Please see full prescribing information at www.SUSTOL.com.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the potential additional market opportunity for the ZYNRELEF expanded U.S. label; the timing and results of studies for the further expansion of the U.S. label for ZYNRELEF; the timing of the commercial launch of ZYNRELEF in Europe; the potential market opportunities for ZYNRELEF in the U.S. and Europe; the timing of the NDA review process for HTX-019 and whether the FDA approves HTX-019; the net product sales guidance for the oncology care franchise; the expected future balances of Heron's cash, cash equivalents and short-term investments; the expected duration over which Heron's cash, cash equivalents and short-term investments balances will fund its operations; the extent of the impact of the ongoing COVID-19 pandemic on our business; and other risks and uncertainties identified in the Company's filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Heron Therapeutics, Inc. | ||||||||
Consolidated Statements of Operations | ||||||||
(In thousands, except per share amounts) | ||||||||
Three Months Ended | Twelve Months Ended | |||||||
2021 | 2020 | 2021 | 2020 | |||||
(Unaudited) | ||||||||
Revenues: | ||||||||
Net product sales | $ 20,655 | $ 20,605 | $ 86,346 | $ 88,638 | ||||
Operating expenses: | ||||||||
Cost of product sales | 10,941 | 9,392 | 46,021 | 36,189 | ||||
Research and development | 28,877 | 44,453 | 130,821 | 174,533 | ||||
General and administrative | 9,887 | 12,503 | 40,153 | 42,226 | ||||
Sales and marketing | 24,487 | 15,553 | 87,179 | 63,853 | ||||
Total operating expenses | 74,192 | 81,901 | 304,174 | 316,801 | ||||
Loss from operations | (53,537) | (61,296) | (217,828) | (228,163) | ||||
Other income (expense), net | (1,109) | (985) | (2,855) | 885 | ||||
Net Loss | $ (54,646) | $ (62,281) | $ (220,683) | $ (227,278) | ||||
Basic and diluted net loss per share | $ (0.54) | $ (0.68) | $ (2.24) | $ (2.50) | ||||
Shares used in computing basic and diluted net loss per share | 101,978 | 91,081 | 98,471 | 90,774 | ||||
Heron Therapeutics, Inc. | ||||
Consolidated Balance Sheets | ||||
(in thousands) | ||||
December 31, | December 31, | |||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $ 90,541 | $ 105,138 | ||
Short-term investments | 67,039 | 103,353 | ||
Accounts receivable, net | 35,499 | 41,850 | ||
Inventory | 48,382 | 41,905 | ||
Prepaid expenses and other current assets | 12,962 | 21,950 | ||
Total current assets | 254,423 | 314,196 | ||
Property and equipment, net | 23,734 | 22,737 | ||
Right-of-use lease assets | 9,829 | 16,277 | ||
Other assets | 17,720 | 346 | ||
Total assets | $ 305,706 | $ 353,556 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
Current liabilities: | ||||
Accounts payable | $ 3,803 | $ 525 | ||
Accrued clinical and manufacturing liabilities | 23,716 | 49,962 | ||
Accrued payroll and employee liabilities | 15,263 | 13,597 | ||
Other accrued liabilities | 25,859 | 28,369 | ||
Current lease liabilities | 2,417 | 2,997 | ||
Convertible notes payable to related parties, net of discount | — | 7,053 | ||
Total current liabilities | 71,058 | 102,503 | ||
Non-current lease liabilities | 7,996 | 14,561 | ||
Non-current convertible notes payable, net | 149,082 | — | ||
Total liabilities | 228,136 | 117,064 | ||
Stockholders' equity: | ||||
Common stock | 1,020 | 913 | ||
Additional paid-in capital | 1,689,987 | 1,628,070 | ||
Accumulated other comprehensive income (loss) | (6) | 257 | ||
Accumulated deficit | (1,613,431) | (1,392,748) | ||
Total stockholders' equity | 77,570 | 236,492 | ||
Total liabilities and stockholders' equity | $ 305,706 | $ 353,556 | ||
Investor Relations and Media Contact:
David Szekeres
Executive Vice President, Chief Operating Officer
Heron Therapeutics, Inc.
dszekeres@herontx.com
858-251-4447
View original content:https://www.prnewswire.com/news-releases/heron-therapeutics-announces-financial-results-for-the-three-and-twelve-months-ended-december-31-2021-and-highlights-recent-corporate-updates-301491850.html
SOURCE Heron Therapeutics, Inc.
FAQ
What were Heron Therapeutics' net product sales for Q4 2021?
What is the expected guidance for Heron's oncology care franchise in Q1 2022?
How much did Heron lose in Q4 2021?
What improvements were made in Heron's net loss for FY 2021 compared to 2020?
What was the impact of ZYNRELEF's launch on Heron's sales?
